LUPIN

Lupin vs Peers

₹2,006.70-1.11%
Market cap
₹91,742 crore
P/E
16.6
P/B
4.09
ROE
26.9%
Dividend yield
0.90%

Lupin ranks 10th by market capitalisation among 71 Pharmaceuticals companies tracked by ATS. Its largest peers are Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals. Its P/E of 16.6 compares with a peer median of 35.5.

Lupin vs Pharmaceuticals peers

Sorted by market capitalisation.

Lupin and peers compared on size, valuation and returns
CompanyClose (₹)1DMarket cap (₹ cr)P/EP/BROE1Y return
Sun Pharmaceutical Industries1,773.60-1.69%4,25,54635.25.0914.7%+12.5%
Divi's Laboratories9,586.00+0.38%2,54,47887.015.1816.2%+12.5%
Torrent Pharmaceuticals4,693.90-1.64%1,58,86372.818.9427.1%+12.5%
Zydus Lifesciences1,151.30-0.71%1,15,84825.74.2719.7%+12.5%
Laurus Labs2,052.90+0.14%1,10,827101.420.9118.2%+12.5%
Cipla1,333.00-0.54%1,07,67732.03.1311.8%+12.5%
Mankind Pharma2,496.00-0.16%1,03,04250.46.3212.5%+12.5%
Dr. Reddy's Laboratories1,194.90-1.08%99,53330.12.6012.1%+12.5%
Aurobindo Pharma1,677.90-0.88%97,45326.32.579.9%+12.5%
Lupin2,006.70-1.11%91,74216.64.0926.9%+22.0%
Glenmark Pharmaceuticals2,286.10-1.08%64,51435.96.1414.1%+12.5%

Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.

Lupin peer comparison — frequently asked questions

Who are Lupin's competitors?

Lupin's listed peers in Pharmaceuticals include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Laurus Labs and Cipla, ranked here by market capitalisation.

How does Lupin's P/E compare with its peers?

Lupin trades at a P/E of 16.6, against a median of 35.5 across the 10 Pharmaceuticals peers shown.

Which is the largest company among Lupin's peers?

By market capitalisation, the largest company in the group is Sun Pharmaceutical Industries at ₹4.26 lakh crore, against ₹91,742 crore for Lupin.

Same Data For Peers

Trade Lupin With ATS

Track LUPIN live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.